<DOC>
	<DOCNO>NCT02257177</DOCNO>
	<brief_summary>This study divide 2 part . Part 1 randomize , double-blind , single centre , placebo-controlled , single ascend dose ( SAD ) phase I study design assess safety , tolerability , PK PD ( Pharmacodynamic ) TD139 36 healthy male subject . Part 2 randomized , double-blind , multi-centre , placebo-controlled , multiple dose expansion cohort , design ass safety , tolerability , PK PD TD139 24 male subject female subject non child-bearing potential IPF .</brief_summary>
	<brief_title>RCT ( Randomized Control Trial ) TD139 v Placebo HV 's ( Human Volunteers ) IPF Patients</brief_title>
	<detailed_description>Up 6 cohort 6 subject randomly assign blinded fashion receive either single dose TD139 match placebo via DPI ( dry powder inhaler ) ascend dose fashion . A single cohort 24 patient randomly assign blind fashion receive single dose TD139 placebo via DPI daily 14 day 2:1 TD139 placebo ratio . The dose TD139 select base data Part 1 pre-clinical efficacy safety data .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Male subject female subject non childbearing potential IPF . Subjects age 45 85 year age . Subjects FVC ( Forced Vital Capacity ) ≥ 45 % predict FEV1 ( Forced Expiratory Flow ) /FVC ratio ≥ 0.7 . Subjects oxygen saturation &gt; 90 % pulse oximetry breathe ambient air rest . Subjects diffuse capacity ( DLCO transfer fact lung carbon monoxide ) &gt; 25 % . Subjects diagnosis consistent IPF prior screen base ATS/ERS/JRS/ALAT ( American , European , Japanese Latin American Respiratory Societies ) consensus criterion . Subjects able undergo bronchoalveolar lavage ( BAL ) . Subjects able provide write informed consent participate study . Subjects negative human immunodeficiency virus ( HIV ) hepatitis B surface antigen ( Hep B ) hepatitis C virus antibody ( Hep C ) result . Subjects clinically significant abnormality 12lead electrocardiogram ( ECG ) determine within 28 day first dose . Subjects negative urinary drug abuse screen , determine within 28 day first dose . Any condition make patient unacceptable risk bronchoscopy . Active cigarette smoking . Presence significant comorbidity felt limit life expectancy le 12 month . HRCT ( high resolution CT scan ) pattern show emphysema extent fibrosis lung area conduct within 12 month Day 1 . Evidence renal , hepatic , central nervous system , metabolic dysfunction . Evidence poorly control diabetes mellitus ( define HbA1c &gt; 59 mmol/mol [ 7.5 % ] ) . Use systemic immunosuppressant within 30 day dose . Subjects currently receive oral corticosteroid , cytotoxic drug ( e.g . chlorambucil , azathioprine , cyclophosphamide , methotrexate ) , antifibrotic drug ( e.g . pirfenidone ) , vasodilator therapy pulmonary hypertension ( e.g bosentan ) , unapproved ( e.g . Interferonγ , penicillamine , cyclosporine , mycophenolate ) and/or investigational therapy IPF administration therapy within 4 week initial screen . History malignancy , include carcinoma precede five year . History , current asthma . Participation clinical study unlicensed drug previous 4 month , market drug study within previous 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>